Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options

Table 1 Summary of patients with epithelioid hemangioendothelioma treated with anti-angiogenic therapy

First author (ref)	No.pts.	Median age	Gender	Treatment medications	Response
Gaur S [6]	1	35	M	Bevacizumab, Nab-Paclitaxel	SD
Belmont [22]	1	41	M	Bevacizumab, Carboplatin, Paclitaxel	PR
Kim [15]	1	44	F	Bevacizumab, Carboplatin, Paclitaxel	PD
Lopes [16]	1	51	M	Bevacizumab, Carboplatin, Etoposide	PD
Mizota [23]	1	59	F	Bevacizumab, Carboplatin, Paclitaxel	PD
Ye [9]	1	44	F	Bevacizumab, Carboplatin, Paclitaxel	SD
Lazarus [24]	1	42	M	Bevacizumab, Paclitaxel	PD
Lazarus [24]	1	42	M	Carboplatin, Etoposide	PD
Salech [25]	1	40	F	Thalidomide	PR
Raphael et al. [26]	1	53	F	Thalidomide	SD
Kassam et al. [27]	1	13	F	Thalidomide	PD
Bolke et al. [28]	1	47	M	Thalidomide	PD
Mascarenhas et al. [29]	1	52	M	Thalidomide	PR
Pallotti et al. [31]	1	73	M	Lenalidomide	SD
Sumrall et al. [30]	1	31	F	Lenalidomide	SD
Agulnik et al. [18]	2	NA	NA	Bevacizumab	PR
	1	NA	NA	Bevacizumab	PD
	4	NA	NA	Bevacizumab	SD
Chevreau et al. [19]	5	NA	NA	Sorafenib	SD
	2	NA	NA	Sorafenib	PR
	8	NA	NA	Sorafenib	PD